23andMe Holding Co
ME
Company Profile
Business description
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
Contact
349 Oyster Point Boulevard
South San FranciscoCA94080
USAT: +1 650 938-6300
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 March 2025
Employees
582
Stocks News & Analysis
stocks
Vote in favour of merger for undervalued ASX share
We recommend shareholders vote in favor of its proposed merger.
stocks
Are investors missing the boat on this future ASX leader?
The market is underestimating the clear path to profitability.
stocks
ASX shares plunge but remain undervalued
Shares drop 17% after guidance is revised but we still see value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,569.10 | 112.30 | 1.33% |
| CAC 40 | 7,629.75 | 155.16 | 2.08% |
| DAX 40 | 20,611.67 | 36.99 | 0.18% |
| Dow JONES (US) | 43,221.55 | 703.27 | 1.65% |
| FTSE 100 | 8,373.01 | 71.88 | 0.87% |
| HKSE | 19,522.89 | 236.82 | 1.23% |
| NASDAQ | 19,511.23 | 466.84 | 2.45% |
| Nikkei 225 | 38,572.60 | 128.02 | 0.33% |
| NZX 50 Index | 13,000.67 | 57.10 | 0.44% |
| S&P 500 | 5,949.91 | 107.00 | 1.83% |
| S&P/ASX 200 | 8,327.00 | 113.70 | 1.38% |
| SSE Composite Index | 3,236.03 | 8.92 | 0.28% |